Centrally Acting Imidazoline I-Receptor Agonists: Do They Have a Place in the Management of Hypertension?

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.1, Iss.5, 2001-01, pp. : 321-326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3760-3770

Bentham Science Publishers

Access to resources Recommend Favorite

I Imidazoline Agonists. General Clinical Pharmacology of Imidazoline Receptors: Implications for the Treatment of the Elderly

By Prichard B.N. Graham B.R.

Drugs & Aging, Vol. 17, Iss. 2, 2000-08 ,pp. : 133-159

Adis International

Access to resources Recommend Favorite

Safe use of long-acting β-agonists: what have we learnt?

By Sears Malcolm R

Expert Opinion on Drug Safety, Vol. 10, Iss. 5, 2011-09 ,pp. : 767-778

Informa Healthcare

Access to resources Recommend Favorite

Fixed-Dose Combinations in the Management of Hypertension: Defining the Place of Angiotensin Receptor Antagonists and Hydrochlorothiazide

By Kjeldsen Sverre E. Os Ingrid Høieggen Aud

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 1, 2005-01 ,pp. : 17-22

Adis International

Access to resources Recommend Favorite

Agonists and Antagonists Acting at P2X7 Receptor

Current Topics in Medicinal Chemistry, Vol. 4, Iss. 16, 2004-12 ,pp. : 1707-1717

Bentham Science Publishers

Access to resources Recommend Favorite